Johnson & Johnson Net Profit Margin 2010-2024 | JNJ

Current and historical net profit margin for Johnson & Johnson (JNJ) from 2010 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue. Johnson & Johnson net profit margin for the three months ending March 31, 2024 was .
Johnson & Johnson Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2024-03-31 $85.65B $38.48B 44.92%
2023-12-31 $85.16B $35.15B 41.28%
2023-09-30 $80.32B $34.62B 43.11%
2023-06-30 $78.97B $13.05B 16.53%
2023-03-31 $77.46B $12.72B 16.43%
2022-12-31 $79.99B $17.94B 22.43%
2022-09-30 $77.21B $19.16B 24.81%
2022-06-30 $80.55B $18.37B 22.80%
2022-03-31 $79.85B $19.83B 24.84%
2021-12-31 $78.74B $20.88B 26.52%
2021-09-30 $91.45B $17.88B 19.55%
2021-06-30 $89.19B $17.77B 19.92%
2021-03-31 $84.21B $15.12B 17.95%
2020-12-31 $82.58B $14.71B 17.82%
2020-09-30 $80.86B $16.99B 21.01%
2020-06-30 $80.50B $15.19B 18.86%
2020-03-31 $82.73B $17.17B 20.75%
2019-12-31 $82.06B $15.12B 18.42%
2019-09-30 $81.71B $14.15B 17.32%
2019-06-30 $81.33B $16.33B 20.08%
2019-03-31 $81.59B $14.68B 17.99%
2018-12-31 $81.58B $15.30B 18.75%
2018-09-30 $81.38B $1.54B 1.89%
2018-06-30 $80.68B $1.37B 1.70%
2018-03-31 $78.69B $1.25B 1.58%
2017-12-31 $76.45B $1.30B 1.70%
2017-09-30 $74.36B $15.83B 21.28%
2017-06-30 $72.53B $16.34B 22.52%
2017-03-31 $72.17B $16.51B 22.87%
2016-12-31 $71.89B $16.54B 23.01%
2016-09-30 $71.60B $15.94B 22.27%
2016-06-30 $70.88B $15.03B 21.20%
2016-03-31 $70.18B $15.55B 22.15%
2015-12-31 $70.07B $15.41B 21.99%
2015-09-30 $70.52B $14.72B 20.87%
2015-06-30 $71.88B $16.11B 22.41%
2015-03-31 $73.59B $15.92B 21.63%
2014-12-31 $74.33B $16.32B 21.96%
2014-09-30 $74.43B $17.32B 23.27%
2014-06-30 $73.54B $15.55B 21.15%
2014-03-31 $71.92B $15.06B 20.94%
2013-12-31 $71.31B $13.83B 19.40%
2013-09-30 $70.52B $12.88B 18.26%
2013-06-30 $69.99B $12.87B 18.38%
2013-03-31 $68.59B $10.44B 15.22%
2012-12-31 $67.22B $10.85B 16.14%
2012-09-30 $65.92B $8.50B 12.90%
2012-06-30 $64.87B $8.74B 13.47%
2012-03-31 $65.00B $10.11B 15.55%
2011-12-31 $65.03B $9.67B 14.87%
2011-09-30 $64.42B $11.40B 17.69%
2011-06-30 $63.40B $11.61B 18.32%
2011-03-31 $62.13B $12.28B 19.77%
2010-12-31 $61.59B $13.33B 21.65%
2010-09-30 $62.49B $13.60B 21.76%
2010-06-30 $62.59B $13.53B 21.61%
2010-03-31 $62.50B $13.29B 21.26%
2009-12-31 $61.90B $12.27B 19.82%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $369.425B $85.159B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $763.090B 110.29
Novo Nordisk (NVO) Denmark $601.464B 46.22
Merck (MRK) United States $332.051B 60.42
AbbVie (ABBV) United States $281.850B 14.56
AstraZeneca (AZN) United Kingdom $244.317B 21.24
Novartis AG (NVS) Switzerland $208.406B 14.78
Pfizer (PFE) United States $167.731B 20.84
Sanofi (SNY) $127.391B 12.02
Innoviva (INVA) United States $1.004B 7.05